World Journal of Oncology最新文献

{"title":"Proliferation Inhibited by Genipin in Human Leukemia K562 Cells: Involvement of Uncoupling Protein 2 in Mitochondrial Damage.","authors":"Ying Zhou, Rui Sun, Zi Wen Zhang, Xin Yi He, Lin Li, Chun Jing Zhang, Ying Liu, Hai Tao Yu","doi":"10.14740/wjon1975","DOIUrl":"10.14740/wjon1975","url":null,"abstract":"<p><strong>Background: </strong>Uncoupling protein 2 (UCP2) is essential for maintaining redox homeostasis and regulating energy metabolism. Abnormal expression of UCP2 has been associated with various tumors, including leukemia. Genipin (GEN), a specific inhibitor of UCP2, has a long history of use in traditional Chinese medicine. However, the precise role and underlying mechanisms of UCP2 in the inhibition of leukemia cells by GEN remain inadequately understood. This study focuses on the expression levels of UCP2 in myeloid leukemia (ML) and investigates the effects of GEN on the proliferation, mitochondrial function, and energy metabolism of the chronic myeloid leukemia (CML) cell line K562.</p><p><strong>Methods: </strong>The expression of UCP2 in clinical samples and cell lines (HL-60, U937, and K562) was confirmed using real-time quantitative polymerase chain reaction (qPCR) and western blot. The effects of GEN on K562 cell viability, morphology, and apoptosis were assessed through a cell counting kit-8 (CCK-8), Wright-Giemsa staining, and an annexin V-fluorescein isothiocyanate/propidium iodide (FITC/PI) apoptosis detection kit. Additionally, the impact of GEN on mitochondrial function and energy metabolism, including reactive oxygen species (ROS), mitochondrial membrane permeability transition pore (MPTP), lactic acid (LA), oxygen consumption rate (OCR), and adenosine triphosphate (ATP) levels in K562 cells, was also examined.</p><p><strong>Results: </strong>The results showed that UCP2 was differentially expressed in clinical samples from patients with ML. Among the three cell lines examined, K562 cells exhibited a significantly higher expression level of UCP2. Functionally, GEN markedly inhibited K562 cell viability while promoting K562 cell differentiation and apoptosis. Mechanistically, UCP2 mRNA and protein expression levels were inhibited by GEN in K562 cells in a concentration- and time-dependent manner. Additionally, GEN dramatically increased ROS generation and induced mitochondrial MPTP opening in K562 cells. Furthermore, GEN significantly reduced LA production in K562 cells and markedly increased OCR and ATP production.</p><p><strong>Conclusion: </strong>The results suggest that UCP2 is differentially expressed in ML patients and cell lines; GEN, a UCP2 inhibitor, induces mitochondrial damage and metabolic remodeling, thereby inhibiting proliferation and promoting apoptosis in K562 cells, and thus could be suggested as an adjuvant of an antitumor metabolic therapy.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"83-94"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>VEGFA</i> Gene Expression in Breast Cancer Is Associated With Worse Prognosis, but Better Response to Chemotherapy and Immunotherapy.","authors":"Pia Sharma, Kohei Chida, Rongrong Wu, Kaity Tung, Kenichi Hakamada, Takashi Ishikawa, Kazuaki Takabe","doi":"10.14740/wjon1993","DOIUrl":"10.14740/wjon1993","url":null,"abstract":"<p><strong>Background: </strong>Vascular endothelial growth factor-A (VEGFA) is a key inducer of angiogenesis, responsible for generating new blood vessels in the tumor microenvironment (TME) and facilitating metastasis. Notably, Avastin, which targets VEGFA, failed to demonstrate any significant benefit in clinical trials for breast cancer (BC). This study aimed to investigate the clinical relevance of <i>VEGFA</i> gene expression in BC.</p><p><strong>Methods: </strong>A total of 7,336 BC patients across eight independent cohorts: ISPY2 (GSE173839), Sweden Cancerome Analysis Network-Breast (SCAN-B) (GSE96058), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), GSE25066, GSE163882, GSE34138, GSE20194, and The Cancer Genome Atlas (TCGA), were analyzed. The calculated median <i>VEGFA</i> expression level was used to stratify these cohorts into high and low groups.</p><p><strong>Results: </strong>High <i>VEGFA</i> was associated with worse disease-free, disease-specific, and overall survival in the METABRIC cohort, with findings supported by the SCAN-B cohort, which also showed worse overall survival (all P < 0.02). High <i>VEGFA</i> expression was seen in triple-negative breast cancer (TNBC) but not in BC with lymph node metastasis. Additionally, there was a significant correlation between high <i>VEGFA</i> expression and higher silent and non-silent mutations, single-nucleotide variant (SNV) neoantigens, homologous recombination defect, intratumoral heterogeneity, in the TCGA cohort. In the TCGA, METABRIC, and SCAN-B cohorts, high <i>VEGFA</i> BC was also associated with higher cell proliferation: higher Ki67 gene expression, higher Nottingham histological grade, and consistent enrichment of all the Hallmark cell proliferation-related gene sets. Unexpectedly, the angiogenesis gene set was not enriched in any of the cohorts and showed no association with infiltrations of lymphatic or blood vascular endothelial cells besides pericytes. High <i>VEGFA</i> BC had significantly less infiltration of anti-cancer immune cells but higher infiltration of pro-cancer immune cells in TCGA, METABRIC, and SCAN-B cohorts. Interestingly, BC, which had a pathological complete response (pCR) after anthracycline- and taxane-based neoadjuvant therapy, was associated with significantly heightened <i>VEGFA</i> expression in both estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- and TNBC subtypes in the GSE25066 cohort and after immunotherapy in ER+/ HER2- subtype, but not TNBC in the ISPY2 cohort.</p><p><strong>Conclusions: </strong>Our research indicates that high <i>VEGFA</i> BC confers high cell proliferation, reduced immune cell infiltration, and poorer survival, but allows better response to anthracycline- and taxane-based chemotherapy, and immunotherapy.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"120-130"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA-155 as Biomarker and Its Diagnostic Value in Breast Cancer: A Systematic Review.","authors":"Bann Siang Yeo, Wen Xuan Lee, Rozi Mahmud, Geok Chin Tan, Mohamed Ibrahim Abdul Wahid, Yoke Kqueen Cheah","doi":"10.14740/wjon1955","DOIUrl":"10.14740/wjon1955","url":null,"abstract":"<p><p>The investigation of microRNAs (miRNAs) for the purpose of identifying biomarkers and new treatments for breast cancer has been gaining traction from scientists in recent years. Of all the miRNAs, miR-155 has been reportedly involved in breast cancer development as it regulates various cellular processes such as glucose uptake, proliferation, metastasis, and migration. Various efforts have been done towards researching miR-155 as a biomarker in breast cancer; however, the results were varied. The objective of the current systematic review is to compile and summarize information regarding miR-155 as a potential diagnostic biomarker for breast cancer. All eligible studies were found from SCOPUS and PubMed databases. Out of the 376 potential eligible records, only 26 original articles were selected for further assessment according to inclusion and exclusion criteria. The expressions of miR-155 in serum, plasma, biopsy, urine, nipple aspirate fluid, serum exosomes, and peripheral blood mononuclear cells were recorded and analyzed. Besides that, the expression of miR-155 was also correlated to clinicopathological features in breast cancer patients. The area under the curve (AUC) values from receiver operating characteristic (ROC) analysis used to evaluate diagnostic sensitivity and specificity of miR-155 as a diagnostic biomarker were also recorded. The limitations such as the small sampling size, the unemployment of internal controls for quantitative real-time polymerase chain reaction (RT-qPCR), and inconsistency of sensitivity as well as specificity values of miR-155 as a biomarker have been discussed. The present study proposed that miR-155 is a good diagnostic biomarker for breast cancer; however, further clinical research is required to assess the validity of miR-155 as a potential biomarker to translate the research outcomes into clinical practice.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"1-15"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between PIK3R1 Expression and Cell Growth in Human Breast Cancer Cell Line BT-474 and Clinical Outcomes.","authors":"Yi-Fang Tsai, Jiun-I Lai, Chun-Yu Liu, Chieh-Ning Hsi, Chih-Yi Hsu, Chi-Cheng Huang, Chin-Jung Feng, Yen-Shu Lin, Ta-Chung Chao, Jen-Hwey Chiu, Ling-Ming Tseng","doi":"10.14740/wjon1986","DOIUrl":"10.14740/wjon1986","url":null,"abstract":"<p><strong>Background: </strong>While mutations in the <i>PIK3CA</i> gene play important roles in human breast carcinogenesis, <i>PIK3R1</i> gene alterations are recognized as actionable mutations for clinical cancer treatment. We aimed to elucidate the role of PIK3R1 in cell proliferation on breast carcinoma and to correlate the PIK3R1 expression with patients' outcome using human tumor tissue arrays.</p><p><strong>Methods: </strong>Using human BT-474 (estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)-high) breast carcinoma cell line as <i>in vitro</i> model, the role of PIK3R1 in cell proliferation was elucidated by knock-down of the <i>PIK3R1</i> gene (ΔPIK3R1) in this cell line. Between January 2000 to December 2015, the records of a cohort of 440 patients in our hospital were retrospectively reviewed, including patients' survival. The correlations between PIK3R1 expression and patient prognosis, such as overall survival (OS) and disease-free survival (DFS), were elucidated by human breast cancer tumor tissue array immunostaining.</p><p><strong>Results: </strong>After the <i>PIK3R1</i> gene was silenced in the BT-474 line, there was an increased cell number and a decrease in the G0G1-fraction, and increased S-fraction and the S+G2M-fraction for the ΔPIK3R1-BT-474 cell line, as compared to their cell wild type (WT) line. Western blot analysis showed that decreased PIK3R1 protein levels were accompanied by an increase of the p-AKT and p-mTOR proteins in the ΔPIK3R1-BT-474 cell line, compared to the equivalent WT line. Using a human tumor tissue array, patients with high-expressed PIK3R1 protein had better outcomes in terms of DFS and OS, compared to those with low-expressed PIK3R1 protein, when breast cancer was at an early stage (stage I/II), but not across all stages of breast cancer in human patients.</p><p><strong>Conclusions: </strong>We concluded that downregulated PIK3R1 in BT-474 cells resulted in an increased cell growth and upregulated AKT-mTOR signaling. Clinically, the high-expressed PIK3R1 protein in tumors correlates positively with patients' outcome in stage I and II breast cancer.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"131-141"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Whey Protein Supplementation on Postoperative Outcomes After Gynecological Cancer Surgery: A Randomized Controlled Trial.","authors":"Wiranchana Chitti, Putsarat Insin, Nisa Prueksaritanond","doi":"10.14740/wjon1990","DOIUrl":"10.14740/wjon1990","url":null,"abstract":"<p><strong>Background: </strong>Whey protein's biochemical properties make it an ideal nutritional supplement for patients with cancer, especially in perioperative care. Thus, the present study aims to assess the efficacy of whey protein supplementation (WPS) compared to standard care in enhancing postoperative outcomes for patients undergoing comprehensive surgical staging for gynecological cancer.</p><p><strong>Methods: </strong>In an open-label, randomized controlled trial conducted at Rajavithi Hospital between November 28, 2023 and July 8, 2024, 61 patients scheduled for comprehensive surgical staging were enrolled. Participants were randomized in a 1:1 ratio to either the WPS group (n = 30) or the control group (n = 31). The WPS group received isolated whey protein powder (20 g of protein per serving), administered at 6 pm before surgery and 6 am on the first postoperative day. The control group received standard postoperative care. The primary endpoint was the length of hospital stay (LOHS), with secondary outcomes including gastrointestinal function recovery, postoperative analgesic use, complications, and potential WPS-related adverse events such as transaminitis, acute kidney injury, and electrolyte imbalances.</p><p><strong>Results: </strong>The WPS group had a significantly shorter LOHS than the control group (79.0 ± 6.7 vs. 93.3 ± 28.4 h, P = 0.021). Additionally, the WPS group demonstrated significant improvements in gastrointestinal function, with shorter times to first flatus (P < 0.001), first defecation (P = 0.013), and first ambulation (P = 0.043). No significant differences were observed between the groups regarding postoperative analgesic use or complications, including fever, nausea/vomiting, wound infection, and readmission (P > 0.05). Furthermore, no WPS-related adverse events were reported.</p><p><strong>Conclusion: </strong>The use of WPS in the perioperative operative management of gynecological cancer surgery yields promising results by significantly reducing the LOHS and accelerating the recovery of gastrointestinal function while maintaining a favorable safety profile.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"70-82"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of 2021 World Health Organization Grading, Peritumoral Edema, and Radiotherapy on the Recurrence of a Grossly Resected Intracranial Meningiomas: A Ten-Year Follow-Up Study.","authors":"Alaa Alkhotani, Saleh Baeesa, Maryam Alshanqiti, Taghreed Alsinani, Ahmed Najjar, Shadi Alkhayyat, Awab Tayyib, Zayed Jastaniah, Abdulrahman J Sabbagh, Nadeem S Butt, Hussain A Alamoudi, Mohammed Alharbi, Basem Bahakeem, Maher Kurdi","doi":"10.14740/wjon1999","DOIUrl":"10.14740/wjon1999","url":null,"abstract":"<p><strong>Background: </strong>The significance of histological grading and peritumoral edema (PTE) in predicting intracranial meningioma recurrence among Saudis is often neglected. This study aimed to evaluate the impact of these factors over a 10-year follow-up period.</p><p><strong>Methods: </strong>A retrospective cohort of 124 patients with intracranial meningioma was analyzed over the period from 2011 to 2021. All patients underwent gross total resection (GTR) of the tumor. Post-surgical radiotherapy (RT) was offered to patients with grade II-III meningiomas. The impact of histological grading, PTE, and RT on the recurrence-free interval (RFI) was investigated.</p><p><strong>Results: </strong>The mean age of the patients was 49 years (range: 18 - 84), with 87 females (70.2%) and 37 males (29.8%). Most tumors (88.7%, n = 110) were supratentorial, while 11.3% (n = 14) were infratentorial. The World Health Organization (WHO) grading classified 101 tumors (81.5%) as grade I, 17 (13.7%) as grade II, and six (4.8%) patients as grade III. Grading was significantly associated with RFI (P = 0.013), with grade I meningiomas having the slowest recurrence. The overall recurrence rate was 16.9%, with 38.1% (n = 8) of grade I and 61.9% (n = 13) of grade II-III meningiomas recurring within 5 years post-GTR and RT. There was no significant difference in RFI between RT-exposed and non-exposed patients (P = 0.15). PTE was present in 76 cases (61.3%) and absent in 48 (38.7%), significantly affecting RFI (P = 0.014), with shorter RFI in PTE cases. Overall, 95.2% (n = 118) of patients survived, while 4.8% (n = 6) died; five had grade II-III, and one had grade I meningioma.</p><p><strong>Conclusions: </strong>Totally, resected intracranial meningiomas with grade II-III features and PTE were associated with earlier tumor recurrence and poorer patient survival. Post-surgical RT had an insignificant effect on the RFI.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"95-103"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression Profile of Thymidine Kinase Genes in Cervical Squamous Cell Carcinoma Confirmed by Various Detection Methods.","authors":"Cai Xia Liang, Ya Jun Pang, Man Yu Chen, Long Nian Hong, Si Xia Huang, Cheng Nong Guan","doi":"10.14740/wjon1962","DOIUrl":"10.14740/wjon1962","url":null,"abstract":"<p><strong>Background: </strong>Thymidine kinases (TKs) are key enzymes involved in DNA synthesis and repair, with alterations in their expression associated with various cancers. Thymidine kinase 1 (TK1) and TK2 are cytosolic enzyme proteins that catalyze the addition of a gamma-phosphate group to thymidine. The existing literature on TK1 in cervical squamous cell carcinoma (CESC) fails to address the clinical role of TK1 overexpression and its possible molecular mechanism in CESC. The clinical significance of TK2 in CESC is also unknown. The objective was to explore the differential expression, clinical significance, and molecular mechanisms of TK1 and TK2 in CESC.</p><p><strong>Methods: </strong>The researchers collected global high-throughput data, extracted the expression levels of TK1 and TK2, and calculated the integrated standardized mean difference (SMD) and summarized receiver's operating characteristics (sROC) of TK1 or TK2 mRNA to investigate the expression profiles of TK genes fully and objectively in 918 CESC tissues and 360 control tissues. In-house tissue microarrays for immunohistochemical testing were used to verify the protein level of TK1 in 62 CESC tissues and control tissues. The growth effect of TK1 and TK2 in CESC cell lines was assessed using Chronos dependency scores derived from CRISPR knockout screen in the Achilles project. We also analyzed the potential mechanism of TK genes by studying the relationship between TK gene expression and immune infiltration, gene alternations as well as the related signal pathways.</p><p><strong>Results: </strong>The various detection methods employed all confirmed that the TK1 expression is upregulated and TK2 is downregulated in CESC tissues (SMD: 2.44, 95% confidence interval (CI): 1.36 - 3.51, area under curve (AUC): 0.88, 95% CI: 0.85 - 0.90; SMD: -0.69, 95% CI: -1.25 to -0.14, AUC: 0.75, 95% CI: 0.71 - 0.78). Inhibition of TK1 expression by CRISPR knockout had negative influence on the biological functions of 11 CESC cell lines. The expression of TK2 was negatively correlated with the malignant progression of CESC. Expression of TK genes showed significant association with the immune infiltration of macrophages, CD4⁺ T cells, and neutrophils. Genes related with TK1 or TK2 were involved in pathways related to DNA replication, proteasome, and homologous recombination.</p><p><strong>Conclusions: </strong>Clinically, these findings suggest that the differential expression of TK1 and TK2 could serve as potential biomarkers, as well as therapeutic targets for personalized treatment strategies in CESC patients.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"30-50"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Analysis of Anaplastic Thyroid Carcinoma With Various Therapeutic Modalities: Twenty-Seven Years' Experience in a Single Cancer Center.","authors":"Putu Anda Tusta Adiputra, I Gede Budhi Setiawan, I Putu Gede Septiawan Saputra, I Wayan Sudarsa","doi":"10.14740/wjon1988","DOIUrl":"10.14740/wjon1988","url":null,"abstract":"<p><strong>Background: </strong>Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid gland malignancy. Several consensuses support the concept of multimodal therapy that combines surgery, radiation, chemotherapy, and targeted therapy. However, patient's comorbidity, poor performance status, and metastasis often make it impossible for patients to undergo multimodal therapy. Therefore, this study aimed to evaluate the survival analysis of ATC patients with different therapeutic modalities.</p><p><strong>Methods: </strong>This study was a retrospective cohort study using data from the Cancer Registry in our institution. All patients with ATC who visited Prof Ngoerah Hospital between 1998 and 2024 were included in this study. Data regarding the survival duration of patients who received treatment modalities, and clinical data were analyzed using SPSS 20.0 with Kaplan-Meier and log-rank tests.</p><p><strong>Results: </strong>Forty-two subjects with ATC were included in the analysis, of which 57.1% were female, with a mean age of 62.57 ± 13.42 years old. The median survival is 27.5 days. This study found no association between survival time and clinical characteristics of the patients (P > 0.05). This study found that patients who received combination therapy such as surgery + chemotherapy/radiotherapy (RT) had a longer survival time (64 days), compared to other patients who received surgery only (26 days), chemotherapy/RT only (49 days), or patients who died before receiving any therapy (19 days). However, the log-rank test showed that it was not statistically different (P > 0.05).</p><p><strong>Conclusion: </strong>ATC survival rates have remained low, and aggressive strategies are still needed to improve the prognosis.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"113-119"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylation of <i>SOX1</i> and <i>PAX1</i> Are Risk Factors and Potential Biomarkers for Cervical Lesions.","authors":"Yan Die Lin, Xiao Yue Li, Li Wei Shao, Ai Jun Liu","doi":"10.14740/wjon1985","DOIUrl":"10.14740/wjon1985","url":null,"abstract":"<p><strong>Background: </strong>The correlation between methylation of paired box gene 1 (<i>PAX1</i>) and sex determining region Y-box 1 (<i>SOX1</i>) with human papillomavirus (HPV) infection and the progression of cervical lesions is not well understood. This study aims to explore the potential value of <i>PAX1</i> and <i>SOX1</i> as diagnostic biomarkers for cervical diseases.</p><p><strong>Methods: </strong>A total of 139 cervical biopsy tissue samples were obtained from the Department of Pathology, the Seventh Medical Center, Chinese PLA General Hospital from 2021 to 2023. The samples include 32 cases of chronic cervicitis (inflammation group), 30 cases of low-grade squamous intraepithelial lesions (LSIL group), 50 cases of high-grade squamous intraepithelial lesions (HSIL group), and 27 cases of cervical squamous cell carcinoma (CSCC group). DNA was extracted from paraffin-embedded tissues, and the levels of HPV infection and methylation of <i>PAX1</i> and <i>SOX1</i> were detected.</p><p><strong>Results: </strong>The methylation index (M-index) of <i>PAX1</i> and <i>SOX1</i> in the HSIL and CSCC groups is significantly higher than in the inflammation group (both P < 0.0001), with no significant difference between the LSIL and inflammation groups. There is no significant difference in the positive <i>PAX1</i> and <i>SOX1</i> methylation rate with HPV infection and age. The positive rates of <i>PAX1</i> methylation in the inflammation, LSIL, HSIL, and CSCC groups were 3.13%, 10.00%, 44.00%, and 88.89%, respectively. The positive rates of <i>SOX1</i> methylation were 3.13%, 10.00%, 40.00%, and 77.78%, respectively, and increasing with the progression of cervical lesions (R² = 0.9189/R² = 0.9279, P < 0.0001/P < 0.0001). Comparing LSIL, HSIL, and CSCC with the inflammation group and using cervical biopsy pathology diagnosis as the gold standard, methylation of <i>PAX1</i> and <i>SOX1</i> is a risk factor for HSIL and CSCC, with odds ratio (OR) values significantly increasing as lesions progress. The sensitivity of <i>PAX1</i> and <i>SOX1</i> methylation to cervical lesions increases with the progression of the lesions.</p><p><strong>Conclusions: </strong>Methylation of <i>SOX1</i> and <i>PAX1</i> is not associated with HPV infection. The positive rate of methylation for <i>SOX1</i> and <i>PAX1</i> is positively correlated with cervical lesions, which can serve as potential biomarkers for HSIL and CSCC. They are risk factors and potential screening indicators for HSIL and above cervical lesions.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"104-112"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discordant Responses Between Imaging Examination and Surgical Pathology of Head and Heck Squamous Cell Carcinoma After Neoadjuvant Immunotherapy Combined With Chemotherapy.","authors":"Yu Dong Ning, Yi Xuan Song, Yu Qin He, Han Li, Shao Yan Liu","doi":"10.14740/wjon1973","DOIUrl":"10.14740/wjon1973","url":null,"abstract":"<p><strong>Background: </strong>We here investigated the value of imaging examination in evaluating tumor remission-based surgery in patients with head and neck squamous cell carcinoma (HNSCC), who had undergone neoadjuvant immunotherapy combined with chemotherapy (NICC).</p><p><strong>Methods: </strong>HNSCC patients who underwent NICC and surgery from May 2021 to September 2023 were retrospectively analyzed. All patients had to undergo imaging examination evaluation, including enhanced computed tomography (CT) and enhanced magnetic resonance (MR) imaging before and after NICC. Data related to clinical parameters, complete response of the primary site (PrCR), complete response of the primary site and the lymph node (PLCR), complete response of the lymph node (LCR), and tumor response (TR), were gathered. The paired Chi-square test and <i>t</i>-test were conducted to analyze the differences in responses between imaging examination and pathology. Binary logistic regression was applied to analyze the relevant clinical factors of differences in responses.</p><p><strong>Results: </strong>In total, data of 41 patients were included in this study. Significant discordant responses were observed between enhanced CT, magnetic resonance imaging (MRI), and pathology in PrCR (4.9%, 7.3% vs. 41.5%), LCR (12.2%, 7.3% vs. 53.7%), PLCR (0%, 0% vs. 31.7%), and TR (severe 29.3%,17.1% vs. 25.61%) (P < 0.05). Patients with hypopharyngeal cancer (odds ratio (OR): 7.04), oral cancer (OR: 3.64), higher neutrophil to lymphocyte ratio (NLR) (OR: 2.05), and earlier T stage (OR: 0.71) exhibited a larger response difference between enhanced CT and pathology. Patients with younger age (OR: 0.79) hypopharyngeal cancer (OR: 22.81), oral cancer (OR: 2.65), higher NLR (OR: 19.47), and earlier T stage (OR: 0.29) exhibited a larger response difference between enhanced MR and pathology.</p><p><strong>Conclusions: </strong>Discordant responses were noted between the imaging examination and surgical pathology of HNSCC after NICC. Hypopharyngeal cancer, higher NLR, and earlier T stage may predict a higher response difference.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 1","pages":"59-69"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}